48 results on '"Hivert, Bénédicte"'
Search Results
2. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
3. A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study.
4. Risk Stratification in Waldenström Macroglobulinemia
5. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia
6. A revised international prognostic score system for Waldenström’s macroglobulinemia
7. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
8. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study
9. A Low Effective Dose of Interleukin-7 Is Sufficient to Maintain Cord Blood T Cells Alive without Potentiating Allo-Immune Responses
10. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
11. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
12. High frequency of central nervous system involvement in transformed Waldenstrom macroglobulinemia
13. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)
14. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
15. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenström macroglobulinemia
16. Risk Stratification in Waldenström Macroglobulinemia
17. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients
18. Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group
19. High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia
20. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
21. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )
22. A prognostic index predicting survival in transformed Waldenstrom macroglobulinemia
23. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
24. Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
25. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
26. A prognostic index predicting survival in transformed Waldenström macroglobulinemia
27. Effects of sphingolipids overload on red blood cell properties in Gaucher disease
28. A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease
29. Natural history of untreated patients with type 1 Gaucher disease
30. Untreated patients with type 1 Gaucher disease: who are they? Resultas from the Gaucher Non-Treated study (GANT study)
31. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
32. Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype
33. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
34. Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group
35. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
36. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
37. A Low Effective Dose of Interleukin-7 is Sufficient to Maintain Cord Blood T Cells Alive without Potentiating Allo-Immune Responses
38. Outcome of Patients Receiving Venetoclax for Chronic Lymphocytic Leukemia (CLL) in Real-Life Clinical Practice: Results of the French ATU Program on Behalf of the Filo Group
39. Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis
40. Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma
41. Impact Of Initial FGD-PET CT and Serum Free Light Chain On Transformation Of Solitary Plasmacytoma To MM
42. Safety Profile Of Bortezomib Impacts Survival Of Cardiac AL Amyloidosis
43. Prognostic Of IgD Myeloma In The Era Of Novel Agents
44. Clinical and Prognostic Implications of Low or High Level of Von Willebrand Factor (VWF) In Waldenström Macroglobulinemia (WM) Patients (pts). A Clinicopathological Study on 72 Pts
45. Prognostic Value of PINI in Elderly Patients with Multiple Myeloma (MM).
46. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
47. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
48. Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.